Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

PYPD vs AVTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PYPD Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–3 Matrix Metrics)

PYPD Overall Winner 6-Pillar Tally: PYPD 2 – 2 AVTX (2 Tie) Matrix Metrics: PYPD 4 – 3 AVTX

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas AVTX carries 49.6/100 (HOLD) at $6.97 (N/M Forward P/E, -161962.7% operating margin).

  • Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (49.6/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -161962.7% operating margin) and revenue trajectory (+0.0% vs. -69.3% YoY).
  • Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 63.2); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PYPD vs AVTX
PYPD NASDAQ Head-to-Head Winner
PolyPid Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.43
+4.63% 1D
Market Cap $132.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.89β · 59% Vol
Unified Composite Score
31.1 / 100 SELL
Tech 50.0 Fund 27.0 Flow 56.0 Mom 32.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 63
RSI-14: 63.2 · SMA20: $5.80 · SMA50: $5.40
AVTX NASDAQ
Avalo Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$6.97
-5.36% 1D
Market Cap $448.7M
TTM Revenue $59,000
Forward P/E N/M
Beta / 30D Vol 1.73β · 164% Vol
Unified Composite Score
49.6 / 100 HOLD
Tech 69.0 Fund 65.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.1%), weak momentum, RSI 34
RSI-14: 34.0 · SMA20: $7.49 · SMA50: $11.83

6-Pillar Scorecard Institutional Category Breakdown (PYPD 2 – 2 AVTX)

Columns: Metric · PYPD · AVTX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AVTX
Revenue Growth (YoY) +0.0% -69.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $59,000
Market Cap $132.2M $448.7M
3. Profitability & Quality PYPD
Gross Margin N/A N/A
Operating Margin 0.0% -161962.7%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -243.6% -33.6%
4. Balance Sheet & Cash Flow AVTX
Cash Generation (TTM) N/A -$63M
Cash Flow Margin N/A N/A
Net Cash / Leverage $5.0M Net Cash $65M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PYPD
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 106.3% (12th %ile) 114.2% (22nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PYPD (4) vs AVTX (3)
Institutional Metric PYPD AVTX Criterion Row Edge
Market Capitalization
Scale
$132.2M $448.7M Larger Scale AVTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -69.3% Higher Growth PYPD
Operating Margin (TTM)
Profitability
0.0% -161962.7% Higher Margin PYPD
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-243.6% -33.6% Higher ROE AVTX
52-Week Range Position
Momentum
80% ($4–$7) 2% ($7–$24) Stronger Trend PYPD
Beta / 30D Volatility
Risk Regime
0.89β · 59% Vol 1.73β · 164% Vol Lower Realized Risk PYPD
Unified Institutional Score
Composite Signal
31.1 / 100 (SELL) 49.6 / 100 (HOLD) Higher Composite AVTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $59,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($5.0M Net Cash) -$63M ($65M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PYPD +71.68 pp
PYPD: +31.86% · AVTX: -39.82%
3M Horizon PYPD +94.83 pp
PYPD: +28.44% · AVTX: -66.39%
6M Horizon PYPD +92.32 pp
PYPD: +35.19% · AVTX: -57.13%
1Y Horizon PYPD +133.09 pp
PYPD: +79.25% · AVTX: -53.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PYPD vs AVTX. Trailing 12-month operating profitability (PYPD 0.0% vs AVTX -161962.7%) and valuation multiples (PYPD N/M vs AVTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PYPD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-243.6% · N/M
AVTX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$59,000
Gross MarginN/A
Op. Margin-161962.7%
ROE / Fwd P/E-33.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PYPD BREAKOUT
40d in phase · OBV ACCUMULATION
Current IV 106.3%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PYPD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVTX BREAKDOWN
134d in phase · OBV DISTRIBUTION
Current IV 114.2%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact AVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PYPD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $132.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $448.7M market capitalization and -161962.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PYPD vs AVTX Key Questions & Quantitative Answers

As of Nov 17, 2026, PolyPid Ltd. (PYPD) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Options & Positioning). PYPD carries a Unified Composite Score of 31.1/100 (SELL) at $6.43 (N/M Forward P/E, 0.0% operating margin), whereas AVTX carries 49.6/100 (HOLD) at $6.97 (N/M Forward P/E, -161962.7% operating margin). Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (49.6/100 HOLD vs. PYPD 31.1/100 SELL), PYPD captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -161962.7% operating margin) and revenue trajectory (+0.0% vs. -69.3% YoY). Technical & Structure Timing Caution: PYPD trades in a Markup technical trend (BREAKOUT options phase, RSI 63.2); meanwhile AVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVTX leads the Growth & Scale pillar: PYPD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AVTX at -69.3% YoY revenue growth and +0.0% YoY earnings growth on $59,000 TTM revenue (N/A gross margin, -161962.7% operating margin). On trailing 12-month operating scale, PYPD generates N/A in USD-normalized revenue versus $59,000 for AVTX. In operating R&D and SG&A reinvestment, PYPD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVTX.

PYPD and AVTX trade at balanced relative valuation multiples. PYPD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PYPD (-243.6% ROE) versus AVTX (-33.6% ROE) capital efficiency.

In options market volatility and institutional positioning, PYPD carries 106.3% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (0.89β · 59% Vol realized risk). By comparison, AVTX carries 114.2% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.73β · 164% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.